LYSSA
MCID: RBS001
MIFTS: 58

Rabies (LYSSA)

Categories: Infectious diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 74 20 58 54 42 3 44 15 71 32
Lyssa 12 20

Characteristics:

Orphanet epidemiological data:

58
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11260
ICD9CM 34 071
MeSH 44 D011818
NCIt 50 C28182
SNOMED-CT 67 14168008
ICD10 32 A82 A82.9
MESH via Orphanet 45 D011818
ICD10 via Orphanet 33 A82.0 A82.1 A82.9
UMLS via Orphanet 72 C0034494
Orphanet 58 ORPHA770
UMLS 71 C0034494

Summaries for Rabies

MedlinePlus : 42 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to noma and non-secretory myeloma, and has symptoms including fever and pruritus. An important gene associated with Rabies is PML (PML Nuclear Body Scaffold), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs chloroquine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and kidney, and related phenotypes are nausea and vomiting and depressivity

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

CDC : 3 Rabies is a fatal but preventable viral disease. It can spread to people and pets if they are bitten or scratched by a rabid animal. In the United States, rabies is mostly found in wild animals like bats, raccoons, skunks, and foxes. However, in many other countries dogs still carry rabies, and most rabies deaths in people around the world are caused by dog bites. The rabies virus infects the central nervous system. If a person does not receive theappropriate medical care after a potential rabies exposure, the virus can cause disease in the brain, ultimately resulting in death. Rabies can be prevented by vaccinating pets, staying away from wildlife, and seeking medical care after potential exposures before symptoms start.

Wikipedia : 74 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 noma 10.4 NGFR ALB
2 non-secretory myeloma 10.4 NCAM1 ALB
3 bolivian hemorrhagic fever 10.3 STAT1 DDX58
4 zika fever 10.3 TLR3 STAT2 DDX58
5 sting-associated vasculopathy with onset in infancy 10.3 STAT1 IRF3 DDX58
6 immunodeficiency 35 10.3 STAT2 STAT1 IFNA1
7 chronic intestinal vascular insufficiency 10.3 DYNLL1 ALB
8 parainfluenza virus type 3 10.3 IFNA1 DDX58
9 subacute sclerosing panencephalitis 10.3 TLR3 MX1 IFNA1
10 chickenpox 10.3 STAT1 IFNA1 ALB
11 fanconi anemia, complementation group c 10.3 STAT1 IFNA1 ALB
12 immunodeficiency 27a 10.3 STAT1 IFNA1
13 anus disease 10.3 TLR3 IFNA1 ALB
14 lassa fever 10.3 IRF3 IFNA1 DDX58
15 rectal disease 10.3 TLR3 IFNA1 ALB
16 poliomyelitis 10.3 TLR3 IFNA1 DDX58
17 noonan syndrome 4 10.3 IRF3 IFNA1 DDX58
18 west nile fever 10.3 IRF3 IFNA1 CXCL10
19 chilblain lupus 1 10.3 IRF3 IFNA1 DDX58
20 dengue shock syndrome 10.3 STAT2 IFNA1 ALB
21 hepatitis e 10.3 TLR3 DDX58 ALB
22 biliary atresia 10.3 TLR3 MX1 ALB
23 hepatitis a 10.3 TLR3 IFNA1 ALB
24 west nile virus 10.3 IRF3 IFNA1 DDX58
25 superficial basal cell carcinoma 10.2 TLR3 IFNA1
26 conjunctival disease 10.2 IFNA1 CCL5 ALB
27 human cytomegalovirus infection 10.2 IRF3 HLA-G CCL5
28 chikungunya 10.2 STAT1 DDX58 CCL5
29 hypersensitivity reaction type iv disease 10.2 IFNA1 CXCL10 ALB
30 adult dermatomyositis 10.2 MX1 IFNA1
31 venezuelan equine encephalitis 10.2 STAT2 STAT1 IFNA1 CXCL10
32 swine influenza 10.2 MX1 IRF3 IFNA1 DDX58
33 vaccinia 10.2 STAT2 STAT1 IRF3 IFNA1
34 viral hepatitis 10.2 TLR3 MX1 IFNA1 ALB
35 meningoencephalitis 10.2 CXCL10 CCL5 ALB
36 leukocyte disease 10.2 NCAM1 IFNA1 ALB
37 potocki-shaffer syndrome 10.2 TLR3 IFNA1 CXCL10
38 pyelonephritis 10.2 CXCL10 CCL5 ALB
39 covid-19 10.2 STAT1 IFNA1 CXCL10
40 hantavirus hemorrhagic fever with renal syndrome 10.2 MX1 DDX58 CXCL10 ALB
41 hepatitis 10.2 IRF3 IFNA1 DDX58 CXCL10
42 ebola hemorrhagic fever 10.2 IRF3 IFNA1 DDX58 CXCL10
43 stomatitis 10.2 MX1 IFNA1 DDX58
44 human immunodeficiency virus infectious disease 10.2 NCAM1 MX1 IFNA1 CCL5
45 trypanosomiasis 10.2 STAT1 HLA-G CXCL10 ALB
46 avian influenza 10.2 STAT2 IFNA1 DDX58 CXCL10
47 crimean-congo hemorrhagic fever 10.2 MX1 IFNA1 DDX58 CXCL10
48 argentine hemorrhagic fever 10.2 IFNA1 DDX58
49 integumentary system disease 10.2 STAT1 IFNA1 CXCL10 ALB
50 viral pneumonia 10.2 TLR3 DDX58 CXCL10 CCL5

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Human phenotypes related to Rabies:

58 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 depressivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0000716
3 hallucinations 58 31 hallmark (90%) Very frequent (99-80%) HP:0000738
4 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
5 attention deficit hyperactivity disorder 58 31 hallmark (90%) Very frequent (99-80%) HP:0007018
6 anxiety 58 31 hallmark (90%) Very frequent (99-80%) HP:0000739
7 anorexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002039
8 paresthesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003401
9 insomnia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100785
10 migraine 58 31 hallmark (90%) Very frequent (99-80%) HP:0002076
11 recurrent pharyngitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100776
12 diarrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002014
13 vocal cord paresis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001604
14 excessive salivation 58 31 hallmark (90%) Very frequent (99-80%) HP:0003781
15 cerebral palsy 58 31 frequent (33%) Frequent (79-30%) HP:0100021
16 sudden cardiac death 58 31 occasional (7.5%) Occasional (29-5%) HP:0001645
17 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
18 seizure 31 occasional (7.5%) HP:0001250
19 seizures 58 Occasional (29-5%)
20 behavioral abnormality 58 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

GenomeRNAi Phenotypes related to Rabies according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.93 NCAM1
2 Decreased viability GR00249-S 9.93 ALB HLA-G MX1 PTPN4 TLR3
3 Decreased viability GR00342-S-1 9.93 TLR3
4 Decreased viability GR00342-S-2 9.93 TLR3
5 Decreased viability GR00381-A-1 9.93 DYNLL1
6 Decreased viability GR00386-A-1 9.93 ALB DHX58 DYNLL1 HLA-G OCA2 STAT2
7 Decreased viability GR00402-S-2 9.93 AAK1 DHX58 NPY TLR3
8 Increased the percentage of infected cells GR00402-S-1 8.32 TLR3

MGI Mouse Phenotypes related to Rabies:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 AAK1 CCL5 CXCL10 DDX58 DHX58 DYNLL1
2 cellular MP:0005384 10.06 ALB CXCL10 DDX58 DHX58 DYNLL1 IRF3
3 homeostasis/metabolism MP:0005376 10.03 AAK1 ALB CXCL10 DDX58 DHX58 DYNLL1
4 immune system MP:0005387 9.83 ALB CCL5 CXCL10 DDX58 DHX58 DYNLL1
5 mortality/aging MP:0010768 9.44 AAK1 ALB CXCL10 DDX58 DHX58 DYNLL1

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Atovaquone Approved Phase 4 95233-18-4 74989
4
Proguanil Approved Phase 4 500-92-5 4923
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Metronidazole Approved Phase 4 443-48-1 4173
7
Vancomycin Approved Phase 4 1404-90-6 441141 14969
8
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
9 Antibodies, Blocking Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Analgesics, Non-Narcotic Phase 4
12 Antimalarials Phase 4
13 Amebicides Phase 4
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4
15 Antirheumatic Agents Phase 4
16 Analgesics Phase 4
17 Chloroquine diphosphate Phase 4 50-63-5
18 Antimetabolites Phase 4
19 Atovaquone, proguanil drug combination Phase 4
20 Anthelmintics Phase 4
21 Anti-Infective Agents Phase 4
22 Anti-Bacterial Agents Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25 Antibiotics, Antitubercular Phase 4
26
Lactitol Approved, Investigational Phase 3 585-86-4 157355
27
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
28
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
29
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
30 gamma-Globulins Phase 3
31 Rho(D) Immune Globulin Phase 3
32 Pharmaceutical Solutions Phase 3
33
Histidine Investigational, Nutraceutical Phase 3 71-00-1 6274
34
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
35 Antibodies, Monoclonal Phase 2
36
Aluminum sulfate Approved Phase 1 10043-01-3
37
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 68-26-8, 11103-57-4 445354
39 polysaccharide-K Phase 1
40 retinol Phase 1
41 Retinol palmitate Phase 1
42 Adjuvants, Immunologic Phase 1
43 Immunoglobulin G
44 Immunoglobulins, Intravenous Early Phase 1

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Unknown status NCT03656198 Phase 4 Sterile Water Injection
2 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
3 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
4 Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP) Completed NCT03741270 Phase 4
5 An Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine(SPEEDA/TRCS SPEEDA) and Rabies Immunoglobulin Completed NCT01137045 Phase 4
6 Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population. Completed NCT00260351 Phase 4
7 A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children Completed NCT02991872 Phase 4
8 A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects Completed NCT01365494 Phase 4
9 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
10 Phase 4 Study of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
11 Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years Completed NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
12 Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
13 A Prospective Randomized Open Label Trial to Study the Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics Recruiting NCT03557008 Phase 4 Metronidazole;Vancomycin;Neomycin Sulfate
14 A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children Withdrawn NCT03192371 Phase 4
15 A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
16 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Unknown status NCT02912845 Phase 3 KamRAB - HRIG
17 Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. Completed NCT00345319 Phase 3
18 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
19 A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China Completed NCT00825305 Phase 3
20 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans From 10-60 Years Old Completed NCT02288286 Phase 3
21 Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New "4-sites, 1-week" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended "2-sites, TRC" Intradermal Regimen in Children and Adults Subjects. Completed NCT02177032 Phase 3
22 Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children Completed NCT01148459 Phase 3
23 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
24 A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years Completed NCT02491541 Phase 3
25 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China Completed NCT01339312 Phase 3
26 A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects. Completed NCT01662440 Phase 3
27 A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined Completed NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
28 Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age) Completed NCT01107275 Phase 3
29 A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults Completed NCT01680016 Phase 3
30 Verorab® Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years Completed NCT01622062 Phase 3
31 Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year Completed NCT03700242 Phase 3
32 Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine in Chinese Healthy People Aged 10-60 Years.: A Randomized, Blinded, Phase III Clinical Trial. Completed NCT03971370 Phase 3
33 A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects Completed NCT03264157 Phase 2, Phase 3 HRIG;HyperRAB
34 A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks Recruiting NCT04644484 Phase 3
35 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) Using the Zagreb Regimen as Simulated Rabies Post-exposure Prophylaxis in Healthy Adults in Thailand Recruiting NCT04594551 Phase 3
36 Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free (VRVg) Assessed With the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Regimens as Simulated Rabies Post-exposure Prophylaxis in Healthy Subjects in Thailand Recruiting NCT04478084 Phase 3
37 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post Primary Series in a Subset of Adults in Thailand Active, not recruiting NCT04127786 Phase 3
38 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France Active, not recruiting NCT03965962 Phase 3
39 A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine. Active, not recruiting NCT02545517 Phase 3
40 One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults. Unknown status NCT02276625 Phase 2
41 A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects Completed NCT02956746 Phase 1, Phase 2
42 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free When Administered According to a Simulated Rabies Post-exposure Regimen in Healthy Adults Completed NCT03145766 Phase 2
43 A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects Completed NCT01228383 Phase 2
44 A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents Completed NCT00708084 Phase 2
45 A Phase II, Pilot, Randomized, Open-Label, Single-Center Study to Evaluate Immunogenicity, Safety and Booster Response of 3 Full Intramuscular Doses Versus 3 Half Intramuscular Doses Versus 3 Intradermal Doses Versus 2 Intradermal Doses of PCEC Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine as a Pre-Exposure Regimen in 12 to 18 Months Old Toddlers in Thailand. Completed NCT00694460 Phase 2
46 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults Completed NCT01877395 Phase 2
47 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
48 Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali Completed NCT01341704 Phase 2
49 A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
50 Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

40
Brain, Cortex, Kidney, Spinal Cord, Skin, T Cells, Eye

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 14035)
# Title Authors PMID Year
1
Assessment of the content, usability, and benefits of the WeChat-based programme for dog bite victims in China: A prospective observation study. 61 42
33327351 2020
2
Virulence mismatches in index hosts shape the outcomes of cross-species transmission. 61 42
33122433 2020
3
Comparing clinical protocols for the treatment of human rabies: the Milwaukee protocol and the Brazilian protocol (Recife). 61 42
33174958 2020
4
Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. 54 61
17400066 2007
5
Immunohistochemical evaluation of mx protein expression in canine encephalitides. 61 54
17099155 2006
6
Expression of the interferon-alpha/beta-inducible bovine Mx1 dynamin interferes with replication of rabies virus. 61 54
16202617 2006
7
Modulation of HLA-G expression in human neural cells after neurotropic viral infections. 54 61
16306594 2005
8
High level of Bcl-2 counteracts apoptosis mediated by a live rabies virus vaccine strain and induces long-term infection. 61 54
14554083 2003
9
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. 61 54
12660934 2003
10
B-cell responses to myelin basic protein and its epitopes in autoimmune encephalomyelitis induced by Semple rabies vaccine. 61 54
10430042 1999
11
Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. 54 61
9345046 1997
12
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation. 54 61
8432980 1993
13
Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. 61 54
2058261 1991
14
Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. 54 61
2153188 1990
15
Neglected challenges in the control of animal rabies in China. 61
33553562 2021
16
Occurrence and diversity of Sarcocystidae protozoa in muscle and brain tissues of bats from São Paulo state, Brazil. 61
33537206 2021
17
Whole-brain efferent and afferent connectivity of mouse ventral tegmental area melanocortin-3 receptor neurons. 61
32856297 2021
18
U.S.-Japan cooperative medical sciences program: 22nd International Conference on Emerging Infectious Diseases in the Pacific Rim. 61
33454559 2021
19
Rabies vaccination inducing eruptive lichen planus in a child. 61
32697851 2021
20
Increasing rabies data availability: The example of a One Health research project in Chad, Côte d'Ivoire and Mali. 61
33385360 2021
21
Using data-driven approaches to improve delivery of animal health care interventions for public health. 61
33468627 2021
22
Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer's Disease. 61
32787268 2021
23
Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice. 61
32995678 2021
24
Early diagnosis of rabies virus infection by RPA-CRISPR techniques in a rat model. 61
33544254 2021
25
Publisher Correction: Rabies Vaccine Characterization by Nanoparticle Tracking Analysis. 61
33526863 2021
26
Time to revise the strategy for Gavi funding of rabies vaccine? 61
33549185 2021
27
Neuroimaging Findings in Rabies Encephalitis. 61
33534937 2021
28
Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial. 61
32783769 2021
29
Temporal and spatial distributions of animal and human rabies cases during 2012 and 2018, in Tunisia. 61
33570258 2021
30
Vaccinating children in high-endemic rabies regions: what are we waiting for? 61
33568394 2021
31
Evolutionary analysis of rabies virus using the partial Nucleoprotein and Glycoprotein gene in Mumbai region of India. 61
33544071 2021
32
Challenges to the Fight against Rabies-The Landscape of Policy and Prevention Strategies in Africa. 61
33579043 2021
33
Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. 61
33563087 2021
34
Multi-annual performance evaluation of laboratories in post-mortem diagnosis of animal rabies: Which techniques lead to the most reliable results in practice? 61
33544702 2021
35
Rabies encephalitis in a preschool child following postexposure prophylaxis. 61
33600470 2021
36
The Role of Waste Management in Control of Rabies: A Neglected Issue. 61
33535718 2021
37
Regional and age difference of human rabies prevalence of the past fourteen years in China. 61
33418517 2021
38
Barriers and opportunities for canine rabies vaccination campaigns in Addis Ababa, Ethiopia. 61
33422971 2021
39
A recombinase polymerase amplification assay for rapid detection of rabies virus. 61
33542337 2021
40
Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis. 61
33478786 2021
41
Modeling anthrax-rabies interactions in zebra-jackal cycles. 61
33333079 2021
42
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. 61
33487468 2021
43
Antemortem diagnosis of human rabies: A case report. 61
33598230 2021
44
Could a rabies incursion spread in the northern Australian dingo population? Development of a spatial stochastic simulation model. 61
33577573 2021
45
Characterizing and Evaluating the Zoonotic Potential of Novel Viruses Discovered in Vampire Bats. 61
33562073 2021
46
Using qualitative approaches to explore the challenges of integrated programmes for zoonosis control in developing countries: Example of hydatidosis control in Morocco. 61
33554481 2021
47
Increased Callosal Connectivity in Reeler Mice Revealed by Brain-Wide Input Mapping of VIP Neurons in Barrel Cortex. 61
33135045 2021
48
The microbiome of bat guano: for what is this knowledge important? 61
33512572 2021
49
Development of a highly sensitive bioanalytical assay for the quantification of favipiravir. 61
33564761 2021
50
Oxytocin-MCH circuit regulates monosynaptic inputs to MCH neurons and modulates social recognition memory. 61
33290754 2021

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TLR3 STAT2 STAT1 PTPN4 PML NCAM1
2
Show member pathways
13.68 TLR3 STAT2 STAT1 OCA2 MX1 IRF3
3
Show member pathways
13.25 STAT2 STAT1 PML NCAM1 MX1 IRF3
4
Show member pathways
12.97 TLR3 STAT2 STAT1 MX1 IRF3 IFNA1
5
Show member pathways
12.91 TLR3 STAT2 STAT1 NGFR MX1 IRF3
6
Show member pathways
12.87 TLR3 STAT2 STAT1 IRF3 IFNA1 HLA-G
7 12.67 TLR3 STAT2 STAT1 PML IRF3 IFNA1
8
Show member pathways
12.48 TLR3 IRF3 IFNA1 DDX58 CXCL10 CCL5
9
Show member pathways
12.44 IRF3 IFNA1 DHX58 DDX58 CXCL10
10
Show member pathways
12.41 TLR3 STAT2 STAT1 PML MX1 IRF3
11
Show member pathways
12.3 STAT2 STAT1 PML NCAM1 MX1 IRF3
12
Show member pathways
12.18 STAT2 STAT1 PML NGFR MX1 IRF3
13 12.17 STAT2 STAT1 IRF3 IFNA1 CCL5
14
Show member pathways
12.09 TLR3 STAT2 STAT1 IFNA1
15 11.84 TLR3 STAT2 STAT1 NCAM1 IRF3 IFNA1
16 11.71 STAT2 STAT1 IFNA1
17
Show member pathways
11.62 TLR3 STAT2 STAT1
18 11.28 STAT2 STAT1 CXCL10
19
Show member pathways
11.02 STAT2 STAT1 MX1 IRF3 DDX58

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TLR3 STAT2 STAT1 PTPN4 PML OCA2

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.2 TLR3 STAT2 STAT1 NGFR MX1 IFNA1
2 immune system process GO:0002376 10.04 TLR3 PML MX1 IRF3 HLA-G DHX58
3 innate immune response GO:0045087 10.03 TLR3 PML MX1 IRF3 DHX58 DDX58
4 viral process GO:0016032 10.01 STAT2 STAT1 PML NCAM1 IRF3 DYNLL1
5 cytokine-mediated signaling pathway GO:0019221 9.93 STAT2 STAT1 IFNA1 CXCL10 CCL5
6 negative regulation of angiogenesis GO:0016525 9.85 STAT1 PML HLA-G CXCL10
7 cellular response to interferon-gamma GO:0071346 9.76 TLR3 STAT1 CCL5
8 positive regulation of interferon-beta production GO:0032728 9.76 TLR3 IRF3 DHX58 DDX58
9 positive regulation of type I interferon production GO:0032481 9.75 TLR3 IRF3 DHX58
10 response to exogenous dsRNA GO:0043330 9.73 TLR3 IRF3 IFNA1 DDX58
11 defense response GO:0006952 9.73 TLR3 STAT2 STAT1 MX1 IFNA1 CXCL10
12 interferon-gamma-mediated signaling pathway GO:0060333 9.72 STAT1 PML NCAM1 IRF3 HLA-G
13 positive regulation of defense response to virus by host GO:0002230 9.7 STAT1 PML DDX58
14 negative regulation of type I interferon production GO:0032480 9.69 IRF3 DHX58 DDX58
15 positive regulation of interferon-alpha production GO:0032727 9.67 TLR3 STAT1 IRF3 DDX58
16 cellular response to exogenous dsRNA GO:0071360 9.65 TLR3 IRF3 DDX58
17 response to virus GO:0009615 9.63 TLR3 MX1 DHX58 DDX58 CXCL10 CCL5
18 positive regulation of T cell migration GO:2000406 9.59 CXCL10 CCL5
19 detection of virus GO:0009597 9.57 TLR3 DDX58
20 type I interferon signaling pathway GO:0060337 9.43 STAT2 STAT1 MX1 IRF3 IFNA1 HLA-G
21 defense response to virus GO:0051607 9.32 TLR3 STAT2 STAT1 PML MX1 IRF3

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TLR3 STAT2 STAT1 PTPN4 PML OCA2
2 double-stranded RNA binding GO:0003725 9.43 TLR3 DHX58 DDX58
3 identical protein binding GO:0042802 9.4 TLR3 STAT2 STAT1 PML NCAM1 MX1
4 CCR5 chemokine receptor binding GO:0031730 9.16 STAT1 CCL5

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....